Výsledky vyhledávání - "Schellens, J. H M"

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Autor: Verheijen, R B, Thijssen, B, Atrafi, F, Schellens, J H M, Rosing, H, de Vries, N, Beijnen, J H, Mathijssen, R H J, Steeghs, N, Huitema, A D R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences, 1104, 234-239. Elsevier
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1104, 234. Elsevier
Journal of Chromatography B, 1104, 234. Elsevier

Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of various tumor types. Less invasive measurement of everolimus concentrations could facilitate pharmacokinetic studies and personalized dosing based on whole blood co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b935e7d3f7902565b922fc9e7abc02
https://pure.eur.nl/en/publications/57d52ca2-2ba2-4212-b234-11a691a53a80

Zobrazit plný text záznamu

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

Autor: Verheijen, R B, Swart, E L, Beijnen, J H, Schellens, J H M, Huitema, A D R, Steeghs, N, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Cancer Chemotherapy and Pharmacology, 86(1). Springer Verlag
Cancer Chemother Pharmacol

Pazopanib is an angiogenesis inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Post hoc analysis of a clinical trial demonstrated a relationship between pazopanib trough concentrations (CRenal cell cancer and soft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::844f5d61a7b34bf1066738a294e735d1
https://dspace.library.uu.nl/handle/1874/410993

Zobrazit plný text záznamu

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

Autor: Henricks, Linda M, Opdam, Frans L, Beijnen, J H, Cats, A., Schellens, J H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Annals of Oncology, 28(12), 2915. Oxford University Press

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine, are frequently prescribed for several types of cancer, including breast, colorectal, head and neck and gastric cancer. In the current drug labels of 5-FU and ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39812f30ab3c9ed25f2b4f2a8a2091a1
https://doi.org/10.1093/annonc/mdx411

Zobrazit plný text záznamu

Akademický článek

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

Autor: Sawicki, E.¹ (AUTHOR) emilia.sawicki@gmail.com, Schellens, J. H. M.^2,3 (AUTHOR), Beijnen, J. H.^1,2,3 (AUTHOR), Nuijen, B.¹ (AUTHOR)

Publikováno v: Drug Development & Industrial Pharmacy. 2017, Vol. 43 Issue 4, p584-594. 11p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma

Autor: van Nuland, Merel, Hillebrand, Michel J X, Rosing, H., Schellens, J H M, Beijnen, J H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Therapeutic Drug Monitoring, 39(3), 243. Lippincott Williams and Wilkins

BACKGROUND: Abiraterone acetate and enzalutamide are 2 novel drugs for the treatment of metastatic castration-resistant prostate cancer. The metabolism of these drugs is extensive. Major metabolites are N-desmethyl enzalutamide, enzalutamide carboxyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::138f4d12ddbdca81d68c1c7613dabb4e
https://doi.org/10.1097/ftd.0000000000000387

Zobrazit plný text záznamu

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Autor: van Andel, Lotte, Zhang, Z, Lu, S., Kansra, V, Agarwal, S., Hughes, L., Tibben, M., Gebretensae, A., Lucas, L., Hillebrand, Michel J X, Rosing, H., Schellens, J H M, Beijnen, J H, Sub Inorganic Chemistry and Catalysis, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Investigational New Drugs
Investigational New Drugs, 35(6), 751. Kluwer Academic Publishers

SummaryNiraparib is an investigational oral, once daily, selective poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor. In the pivotal Phase 3 NOVA/ENGOT/OV16 study, niraparib met its primary endpoint of improving progression-free survival (PFS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24ced89dc5412f38163416b641e29df
http://europepmc.org/articles/PMC5694528

Zobrazit plný text záznamu

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples

Autor: Kip, Anke E, Kiers, K C, Rosing, H, Schellens, J H M, Beijnen, J H, Dorlo, T P C, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology

Publikováno v: Journal of Pharmaceutical and Biomedical Analysis, 135, 160. Elsevier

Miltefosine is an oral agent against the neglected tropical disease leishmaniasis, which is mostly endemic in resource-poor areas. Dried blood spot (DBS) sampling is an attractive alternative to plasma sampling for pharmacokinetic studies in these re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5fd548286a9ee174aba97f6c72eb55
https://doi.org/10.1016/j.jpba.2016.12.012

Zobrazit plný text záznamu

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

Autor: de Haan, R, van Werkhoven, E, van den Heuvel, M M, Peulen, H M U, Sonke, G S, Elkhuizen, P, van den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, van Triest, B, Verheij, M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: BMC Cancer, 19:901. BioMed Central
BMC Cancer, Vol 19, Iss 1, Pp 1-13 (2019)
De Haan, R, Van Werkhoven, E, Peulen, H M U, Sonke, G S, Elkhuizen, P, Van Den Brekel, M W M, Tesselaar, M E T, Vens, C, Schellens, J H M, Van Triest, B & Verheij, M 2019, ' Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib ', BMC Cancer, vol. 19, no. 1, 901 . https://doi.org/10.1186/s12885-019-6121-3
BMC Cancer, 19(1). BioMed Central
BMC Cancer, 19
BMC Cancer, 19(1):901. BioMed Central
BMC cancer, 19(1):901. BioMed Central
BMC Cancer

BackgroundPoly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP inhibitor with a favourable safe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f014ea007d5945e14e36f9eb38186766
https://doi.org/10.1186/s12885-019-6121-3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání